ArticleEJNMMI research2018
Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.Journal of bone oncology · 2025Review
- Non-[Pharmaceuticals (Basel, Switzerland) · 2024Review
- New Developments in Myeloma Treatment and Response Assessment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI.Journal of personalized medicine · 2022Review
- Molecular Imaging in Multiple Myeloma-Novel PET Radiotracers Improve Patient Management and Guide Therapy.Frontiers in nuclear medicine · 2022Review
- Recent developments on the application of molecular probes in multiple myeloma: Beyond [Frontiers in bioengineering and biotechnology · 2022Review
- Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting.Diagnostics (Basel, Switzerland) · 2021Review
- Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma.Frontiers in nuclear medicine · 2021Review
- Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.Molecules (Basel, Switzerland) · 2019Review
- Imaging of T-cells and their responses during anti-cancer immunotherapy.Theranostics · 2019Review
- Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative DynamicCancers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the significant upgrading in recent years of the role of
resultsEight patients, four suffering from symptomatic MM and four suffering from smoldering MM (SMM), were enrolled in the study. All patients underwent
conclusionsDespite the limited number of patients analyzed in this pilot study, the first results of the trial indicate that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.